These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 1804322)

  • 21. Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis.
    Sharma SK; Dube A; Nadeem A; Khan S; Saleem I; Garg R; Mohammad O
    Vaccine; 2006 Mar; 24(11):1800-10. PubMed ID: 16310900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2.
    McLaughlin JP; Schlom J; Kantor JA; Greiner JW
    Cancer Res; 1996 May; 56(10):2361-7. PubMed ID: 8625312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The serologic response to Meth A sarcoma vaccines after cyclophosphamide treatment is additionally increased by various adjuvants.
    Livingston PO; Jones M; Deleo AB; Oettgen HF; Old LJ
    J Immunol; 1985 Aug; 135(2):1505-9. PubMed ID: 4008930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy of murine sarcomas with auto-anti-idiotypic monoclonal antibodies which bind to tumor-specific T cells.
    Nelson KA; George E; Swenson C; Forstrom JW; Hellström KE
    J Immunol; 1987 Sep; 139(6):2110-7. PubMed ID: 2957449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
    Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
    Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo.
    Tahara H; Zeh HJ; Storkus WJ; Pappo I; Watkins SC; Gubler U; Wolf SF; Robbins PD; Lotze MT
    Cancer Res; 1994 Jan; 54(1):182-9. PubMed ID: 7903204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protection of mice against visceral leishmaniasis by immunization with promastigote antigen incorporated in liposomes.
    Ali N; Afrin F
    J Parasitol; 1997 Feb; 83(1):70-5. PubMed ID: 9057699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Administration of systemic or local interleukin-2 enhances the anti-tumor effects of interleukin-12 gene therapy.
    Pappo I; Tahara H; Robbins PD; Gately MK; Wolf SF; Barnea A; Lotze MT
    J Surg Res; 1995 Feb; 58(2):218-26. PubMed ID: 7861776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Preparation oral liposome-encapsulated recombinant Helicobacter pylori heat shock protein 60 vaccine for prevention of Hp infection].
    Huang W; Bai Y; Wang JD; Wu JB; Li GF; Zhang WM; Zhou DY
    Di Yi Jun Yi Da Xue Xue Bao; 2005 May; 25(5):531-4. PubMed ID: 15897126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization. Culture requirements and characterization of immunologic specificity.
    Chou T; Chang AE; Shu SY
    J Immunol; 1988 Apr; 140(7):2453-61. PubMed ID: 2450925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.
    Redlinger RE; Mailliard RB; Lotze MT; Barksdale EM
    J Pediatr Surg; 2003 Mar; 38(3):301-7; discussion 301-7. PubMed ID: 12632339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants.
    Allione A; Consalvo M; Nanni P; Lollini PL; Cavallo F; Giovarelli M; Forni M; Gulino A; Colombo MP; Dellabona P
    Cancer Res; 1994 Dec; 54(23):6022-6. PubMed ID: 7954438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhancement by IL-12 of the cytolytic T lymphocyte (CTL) response of mice immunized with tumor-specific peptides in an adjuvant containing QS21 and MPL.
    Silla S; Fallarino F; Boon T; Uyttenhove C
    Eur Cytokine Netw; 1999 Jun; 10(2):181-90. PubMed ID: 10400824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-CD3 + IL-2-stimulated murine killer cells. In vitro generation and in vivo antitumor activity.
    Anderson PM; Blazar BR; Bach FH; Ochoa AC
    J Immunol; 1989 Feb; 142(4):1383-94. PubMed ID: 2521662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The immunological co-adjuvant action of liposomal interleukin-2: the role of mode of localisation of the cytokine and antigen in the vesicles.
    Gursel M; Gregoriadis G
    J Drug Target; 1998; 5(2):93-8. PubMed ID: 9588865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liposomes, a potential immunoadjuvant and carrier for a cryptococcal vaccine.
    Lambros MP; Schafer F; Blackstock R; Murphy JW
    J Pharm Sci; 1998 Sep; 87(9):1144-8. PubMed ID: 9724568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Depot characteristics and biodistribution of interleukin-2 liposomes: importance of route of administration.
    Anderson PM; Katsanis E; Sencer SF; Hasz D; Ochoa AC; Bostrom B
    J Immunother (1991); 1992 Jul; 12(1):19-31. PubMed ID: 1637781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liposomes containing interferon-gamma as adjuvant in tumor cell vaccines.
    van Slooten ML; Storm G; Zoephel A; Küpcü Z; Boerman O; Crommelin DJ; Wagner E; Kircheis R
    Pharm Res; 2000 Jan; 17(1):42-8. PubMed ID: 10714607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytokine depot formulations as adjuvants for tumor vaccines. I. Liposome-encapsulated IL-2 as a depot formulation.
    Krup OC; Kroll I; Böse G; Falkenberg FW
    J Immunother; 1999 Nov; 22(6):525-38. PubMed ID: 10570751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.